--- title: "This year, China has approved more than ten innovative drugs, and the innovative drug ETF Tianhong (517380) has a trading volume exceeding 5 million yuan. Institutions: The sector is experiencing a dual resonance of fundamentals and sentiment" type: "News" locale: "en" url: "https://longbridge.com/en/news/282474230.md" description: "This year, China has approved more than ten innovative drugs, and the innovative drug ETF Tianhong (517380) has a trading volume exceeding 5 million yuan. The three major indices have mixed performances, with the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 Index down 1.18%. The innovative drug ETF is the only ETF tracking this index, covering the entire industry chain. Data from the National Medical Products Administration shows that 13 innovative drugs have been approved in the first four months of this year, with a total transaction volume of over 60 billion USD for innovative drug licensing deals. Huayuan Securities believes that the innovative drug sector is experiencing a dual resonance of fundamentals and sentiment, with breakthroughs in AI pharmaceutical technology and the international expansion of Chinese innovative drugs creating a dual resonance" datetime: "2026-04-13T02:09:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282474230.md) - [en](https://longbridge.com/en/news/282474230.md) - [zh-HK](https://longbridge.com/zh-HK/news/282474230.md) --- # This year, China has approved more than ten innovative drugs, and the innovative drug ETF Tianhong (517380) has a trading volume exceeding 5 million yuan. Institutions: The sector is experiencing a dual resonance of fundamentals and sentiment On April 13, the three major indices showed mixed results. As of the time of publication, the Shanghai Composite Index fell by 0.38%, the Shenzhen Component Index rose by 0.09%, and the ChiNext Index increased by 0.47%. The Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 Index dropped by 1.18%. Among the constituent stocks of this index, Rongchang Biologics A shares rose over 3%, Junshi Biosciences-U increased by over 2%, and Sanofi China rose by over 1%. In terms of related ETFs, the **Innovative Drug ETF Tianhong (517380)** had a trading volume exceeding 5 million yuan as of the time of publication. The latest circulating share count for this ETF is 2.17 billion shares, with a latest circulating scale of 1.699 billion yuan. The Innovative Drug ETF Tianhong (517380) is the only ETF in the entire market that tracks the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 Index, gathering the strength of China's hardcore innovative drugs and representing new productive forces. It comprehensively covers the entire industry chain from preclinical research to commercialization, allowing for a one-click layout of A-shares + Hong Kong stocks in innovative drugs and leading CXO enterprises. The top ten constituent stocks of the tracked index have a relatively concentrated weight, including leading stocks such as WuXi AppTec and Heng Rui Medicine. On the news front, according to Yicai, the National Medical Products Administration recently released the latest data showing that as of April 10 this year, the National Medical Products Administration has approved 13 innovative drugs for market launch. These drugs cover a range of therapeutic areas from anti-tumor to blood sugar and lipid reduction, addressing various critical diseases, including 6 first-in-class drugs. China's new drug innovation capability is gaining increasing global recognition. The latest statistics from the National Medical Products Administration indicate that the total value of innovative drug licensing transactions in China exceeded 60 billion USD in the first three months of this year, approaching half of the total value for the entire year of 2025. **Huayuan Securities** believes that the innovative drug sector is experiencing a dual resonance of fundamentals and sentiment. The core driving force lies in the strong momentum of outbound licensing (BD) transactions, indicating that Chinese innovative drug assets are gaining high international recognition. Additionally, upcoming international top academic conferences such as AACR and ASCO will disclose a large amount of key clinical data, which is expected to become an important catalyst for the market. **CMB International** points out that the biopharmaceutical industry is positioned to rise as an emerging pillar industry, indicating that the policy dividends across the entire chain will continue to be released. Breakthroughs in AI pharmaceutical technology and the explosive growth of outbound BD for Chinese innovative drugs are forming a dual resonance, with the industry's fundamentals expected to accelerate positively. Currently, domestic innovative drug collaborations for outbound markets have upgraded from single pipeline licensing to platform-level cooperation, and multinational pharmaceutical companies' recognition of China's pharmaceutical R&D capabilities is systematically increasing. ### Related Stocks - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [517380.CN](https://longbridge.com/en/quote/517380.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) ## Related News & Research - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md) - [Worried About a Market Crash? 3 Vanguard ETFs Built to Survive](https://longbridge.com/en/news/286880525.md) - [$100 Invested In iShares S&P 500 Growth ETF 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286800978.md) - [Warren Buffett calls this investment "the right thing for most people." 1 Vanguard ETF makes his case perfectly.](https://longbridge.com/en/news/286651429.md)